Freely Filtered, a NephJC Podcast
Health & Fitness:Medicine
The Filtrate:
Joel Topf
Swapnil Hiremath
Sophia Ambruso
AC Gomez
Josh Waitzman
Jennie Lin
Nayan Arora
The Curbsiders
Matt F. Watto (@DoctorWatto)
Paul Nelson Williams, America’s primary care physician (@PaulNWilliamz)
With Special Guest:
JD Foster (@KidneyVet)
Sayed Tabatabai (@TheRealDoctorT) Nephrologist in Austin and the author of These Vital Signs
Michelle Rheault (@rheault_m) Chief of Pediatric Nephrology at the University of Minnesota and lead author of the DUPLEX Trial
Editor:
Joel Topf
Show Notes:
Lily toxicity in the cat (PubMed)
Surgeons perform kidney transplants in cats amid rising demand for advanced pet care (ABC News)
Treatment of ibuprofen toxicity with serial charcoal hemoperfusion and hemodialysis in a dog (PubMed)
Nephrology in Veterinary Medicine (Kidney 360)
Star Wars Society of San Antonio (FaceBook)
These Vital Signs (Amazon)
Dr Tabatabai read a short story called The Handholder, here is the original tweet thread for that story (ThreadReader)
The pearl not the patient (PubMed)
Late Braking and High Impact Clinical Trial press release
MENTOR, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, was in 2019 not 2017 (NEJM)
KALM-1, A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus, was in 2019 not 2017 (NEJM)
Sophie’s number one pick: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Lancet)
Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058).
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration (AJKD)
AC Gomez’s Pick: MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients (ASN-Online.org)
Josh’s Pick: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (NEJM)
Nayan’s Pick: The EnAKT LKD Cluster Randomized Clinical Trial (JAMA Internal Medicine)
The Freely Filtered simultaneous release (NephJC)
Freely Filtered is now a verb.
Swap’s Pick: Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D) (ASN-Online.org)
Joel’s Pick: AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients (ASN-Online.org)
Reata is a no-show to the 2012 ASN Kidney Week (PBFluids)
Michelle’s Pick: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The DUPLEX Study (NEJM)
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)
Freely Filtered 033: The Roxadustat Statistics shenanigans
Freely Filtered 032: Animal House
Freely Filtered 031: Roxadustat
Freely Filtered 030: DAPA-CKD
Freely Filtered 029: Belimumab for lupus nephritis
Freely Filtered 028: Finerenone for diabetic kidney disease
Freely Filtered 027: Long and deep on the KDIGO Diabetes Guidelines
Freely Filtered 026: Interventional Nephrology meet NephJC, NephJC meet Interventional Nephrology
Freely Filtered 025: Making sense of albuminuria, proteinuria, and the dipstick
Freely Filtered 024: STARRT me up!
Freely Filtered 023: Race and Estimated GFR
Freely Filtered 022: Uric Acid faces the Music.
Freely Filtered 021: Aldosteronism is everywhere
Freely Filtered 020: SGLT2i are diuretics, but not like any other diuretics
Freely Filtered 019: CRIC on NSAIDs v Opioids
Freely Filtered 018: ISCHEMIA-CKD, Courage, and Céline Dion
Freely Filtered 017: COVID Autopsy, Acute PD, and Making CRRT Dialysate
Freely Filtered 016 MinTac trial and COVID-19 Podcast No. 3
Freely Filtered 014 COVID-19 Podcast No. 2
Freely Filtered 013 COVID-19 and the Kidney
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
URGENŤÁCI